4.195 0.405 (10.69%) | 02-19 13:55 | |||||||||||||
|
|
Short term | ![]() ![]() ![]() |
|||
Mid term | ![]() ![]() ![]() |
|||
Targets | 6-month : | 5 ![]() |
1-year : | 5.84 ![]() |
Resists | First : | 4.28 ![]() |
Second : | 5 ![]() |
Pivot price | 3.76 ![]() |
|||
Supports | First : | 3.68 ![]() |
Second : | 3.31 ![]() |
MAs | MA(5) : | 3.69 ![]() |
MA(20) : | 3.71 ![]() |
MA(100) : | 3.2 ![]() |
MA(250) : | 2.35 ![]() |
|
MACD | MACD : | 0 ![]() |
Signal : | 0 ![]() |
%K %D | K(14,3) : | 52.9 ![]() |
D(3) : | 41.3 ![]() |
RSI | RSI(14): 60.6 ![]() |
|||
52-week | High : | 4.28 | Low : | 1.41 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ATYR ] has closed below upper band by 4.9%. Bollinger Bands are 22.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 3.83 - 3.85 | 3.85 - 3.88 |
Low: | 3.46 - 3.49 | 3.49 - 3.52 |
Close: | 3.74 - 3.79 | 3.79 - 3.84 |
Wed, 19 Feb 2025
aTyr Pharma Stock Soars to 52-Week High of $4.22 Amidst Strong Growth - Investing.com
Wed, 19 Feb 2025
Atyr PHARMA INC (NASDAQ:ATYR) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Wed, 19 Feb 2025
Atyr PHARMA (NASDAQ:ATYR) Earns Outperform Rating from Analysts at Leerink Partners - MarketBeat
Tue, 18 Feb 2025
Leerink Partners Initiates Coverage of aTyr Pharma (ATYR) with Outperform Recommendation - Nasdaq
Tue, 18 Feb 2025
This aTyr Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Tue, 18 Feb 2025
Leerink Partners Initiates Coverage on aTyr Pharma With Outperform Rating, $16 Price Target - Marketscreener.com
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 84 (M) |
Held by Insiders | 7.69e+007 (%) |
Held by Institutions | 2.1 (%) |
Shares Short | 3,650 (K) |
Shares Short P.Month | 0 (K) |
EPS | -6.734e+007 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | -28 % |
Return on Assets (ttm) | 958.7 % |
Return on Equity (ttm) | -39.3 % |
Qtrly Rev. Growth | 235000 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | -70.4 |
EBITDA (p.s.) | -4.92432e+007 |
Qtrly Earnings Growth | -1 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -67 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | -0.06 |
Price to Cash Flow | 5.24 |
Dividend | 0 |
Forward Dividend | 3.82e+006 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |